xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 4, 2009 : OPXA, CPTS, EDGW and ATRC

Xtremepicks.com Alerts include Opexa Therapeutics, Inc. (NASDAQ: OPXA), Conceptus, Inc. (Nasdaq: CPTS), Edgewater Technology, Inc. (Nasdaq: EDGW) and AtriCure, Inc. (Nasdaq: ATRC)

Opexa Therapeutics, Inc. (NASDAQ: OPXA) trading at $1.95 on a volume of 134,257 shares

In a press release out on November 4, Opexa Therapeutics Reports Third Quarter 2009 Financial Results and Corporate Update

THE WOODLANDS, Texas, Nov 04, 2009 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2009, and provided details on further developments.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company's leading therapy, Tovaxin, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for MS. Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin, believed to be a primary cause of MS attacks and nervous system damage.

Conceptus, Inc. (Nasdaq: CPTS) trading at $17.39 per share on trading volume of 126,096 shares.

In a press release out on November 4, Conceptus(R) to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov 04, 2009 -- Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure(R) procedure, the first proven non-incisional permanent birth control method available, today announced that Mark Sieczkarek, president and chief executive officer, will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009, at 2:10 p.m. ET. The conference will be held at the St. Regis Hotel in New York City.

About Conceptus, Inc.

Conceptus, Inc. (NASDAQ: CPTS), is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Mountain View, Calif.-based company manufactures and markets Essure permanent birth control. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.

Edgewater Technology, Inc. (Nasdaq:EDGW) trading at $2.99 on a volume of 100 shares

In a press release out on November 4, Edgewater Announces Third Quarter Financial Results

Service Revenue Stabilizes; In Line With Expectations

WAKEFIELD, Mass., Nov 4, 2009 -- A technology management consulting firm specializing in providing specialty information technology ("IT") services, Edgewater Technology, Inc. (Nasdaq:EDGW) (www.edgewater.com) ("Edgewater" or the "Company") today announced financial results for its third quarter ended September 30, 2009.

About Edgewater Technology, Inc.

Edgewater is an innovative technology management consulting firm. We provide a unique blend of specialty IT services by leveraging our proven industry expertise in strategy, technology and enterprise performance management. Headquartered in Wakefield, MA, we typically go to market both vertically by industry and horizontally by product and technology specialty and provide our clients with a wide range of business and technology offerings. To learn more, visitwww.edgewater.com or call 800-410-4014.

AtriCure, Inc. (Nasdaq: ATRC) trading at $4.99 on a volume of 154,620 shares

In a press release out on November 4, AtriCure Reports Third Quarter 2009 Financial Results

Third Quarter Highlights

WEST CHESTER, Ohio, Nov 04, 2009 -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced revenues of $13.3 million for its seasonally light third quarter. The company reported positive adjusted EBITDA, a non-GAAP measure, of $0.7 million for the quarter, representing the third consecutive quarter of positive adjusted EBITDA and year-to-date adjusted EBITDA of $1.7 million.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke. The FDA has cleared the AtriCure Isolator system and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias and AtriCure's Cryo1(TM) system for the cryosurgical treatment of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: australia, business, california, canada, cellular, ceo, clinical, conference, consulting, corporate, ebitda, electrical, email, e-mail, europe, financial results, gaap, health, healthcare, hotel, information technology, investment, investment opinion, manufacturer, manufacturing, market, marketing, massachusetts, medical, mexico, nasdaq, nervous system, new york, new zealand, ohio, president, products, profit, revenue, south america, technology, texas, web, women